目的:确定局部和结膜下无防腐剂的0.1%硫酸吗啡(PFMS)在犬超声乳化术后镇痛中的疗效。
方法:10只接受双侧超声乳化手术的糖尿病和10只非糖尿病患者饲养犬。
方法:前瞻性,随机化,蒙面,进行阴性对照临床试验.在超声乳化后,所有狗在一只眼睛中接受局部(0.2mL)和结膜下(0.1mL)0.1%PFMS。另一只眼睛接受等体积和给药方式的平衡盐溶液(BSS)。眼科检查,闪烁率,撕裂,结膜充血,水性耀斑,在手术前1天和手术后4、24和48小时对所有眼睛进行了中央角膜美学测量(CCE)评估。完成体检,眼超声,视网膜电图,血象,在超声乳化术之前,对所有狗进行血清生化检查。所有的狗在手术前后都接受了标准的护理治疗,包括统一的麻醉方案。
结果:基线眼科检查不明显,除了白内障的存在,在所有的狗。阴性对照组和PFMS组术后4小时的平均CCE(±SD)为1.76±1.27g/mm2和1.85±1.5g/mm2。分别。眼睑痉挛没有统计学差异,结膜充血,撕裂,水性耀斑,闪烁率,CCE,非糖尿病和糖尿病犬的任何时间点的治疗组之间的眼内压(IOP),或所有狗的组合(P>0.05)。
结论:局部和结膜下0.1%PFMS在评估的时间点不影响研究犬超声乳化后的评估参数。
OBJECTIVE: To determine the efficacy of a single treatment of topical and subconjunctival 0.1% preservative-free morphine sulfate (PFMS) in providing analgesia following phacoemulsification in dogs.
METHODS: Ten diabetic and ten non-diabetic client-owned dogs treated with bilateral phacoemulsification.
METHODS: A prospective, randomized, masked, negative-controlled clinical
trial was performed. All dogs received topical (0.2 mL) and subconjunctival (0.1 mL) 0.1% PFMS in one eye following phacoemulsification. The other eye received an equal volume and mode of administration of balanced salt solution (BSS). Ophthalmic examination, blinking rates, tearing, conjunctival hyperemia, aqueous flare, and central corneal esthesiometry (CCE) were evaluated in all eyes 1 day prior to surgery and at 4, 24, and 48 hours after surgery. Complete physical examination, ocular ultrasound, electroretinogram, hemogram, and serum biochemistry panel were performed in all dogs prior to phacoemulsification. All dogs received the standard of care treatment before and after surgery, including uniform anesthetic protocol.
RESULTS: Baseline ophthalmic exams were unremarkable, except for the presence of cataracts, in all dogs. The mean CCE (±SD) at 4 hours post-operatively was 1.76 ± 1.27 g/mm2 and 1.85 ± 1.5 g/mm2 for the negative control and PFMS groups, respectively. There were no statistical differences in blepharospasm, conjunctival hyperemia, tearing, aqueous flare, blinking rates, CCE, or intraocular pressure (IOP) between the treatment groups for any of the time points for the non-diabetic and diabetic dogs, or for all dogs combined (P > .05).
CONCLUSIONS: Topical and subconjunctival 0.1% PFMS did not affect the evaluated parameters after phacoemulsification in the
study dogs at the timepoints assessed.